Reproducibility: The Foundation of Modern Biomedical Research

Biomedical research is undergoing a period of remarkable technological innovation. Stem cell technologies, artificial intelligence and increasingly sophisticated experimental models are transforming how we study disease, understand biological mechanisms and develop new therapeutics. However, the value of these new innovations depends on confidence that discoveries are robust, reproducible and capable of withstanding independent validation. As the volume of published research continues to grow, studies that validate previous findings, optimise methodologies and assess reproducibility become increasingly important. RevisX aims to provide a platform for both cutting-edge biomedical discoveries and the validation, replication and methodological studies that strengthen the scientific record, addressing key challenges in scientific publishing while maintaining scientific impact. In support of RevisX’s mission, I want to present three areas of biomedical research that I believe are particularly well positioned to benefit from an emphasis on reproducibility.

Organoids and disease modelling.

Organoids have become established as one of the most influential and exciting tools in modern biomedical research. By recreating human tissue with increasing complexity, including with appropriate cell populations, vascularisation and tissue-specific conditions like fluid-flow, organoids offer powerful platforms for studying disease mechanisms, investigating developmental biology and evaluating potential therapeutics. Their ability to model patient-specific biology also places them at the forefront of precision medicine [2], [5]. Despite these advances, reproducibility remains one of the greatest challenges facing the field. Organoid differentiation protocols can differ at numerous levels, and may even need cell-specific optimisation, leading to inconsistencies in the models, and analytical methods can produce considerable variation in experimental outcomes between laboratories. Studies that systematically compare methodologies, validate differentiation protocols or establish best practices are therefore invaluable. By promoting transparency and methodological standardisation, the scientific community can improve confidence in organoid-based research and accelerate its translation into clinical applications.

Structural and functional characterisation of disease-relevant proteins.

Structural biology has similarly been transformed by the introduction of modern computational approaches. Artificial intelligence (AI) and machine-learning based tools like AlphaFold have fundamentally altered how protein biology work is conducted, and design methods such as RFdiffusion have created new possibilities for protein engineering [1], [4]. With barriers to structure determination and protein design being reduced, researchers are now able to explore biological questions that would previously have required years of experimental effort. As structural predictions become increasingly accessible, it is important that confidence in computational models does not outpace experimental evidence. The importance of such work cannot be understated, with these kinds of studies fuelling our understanding of disease mechanisms and identifying new methods of clinical intervention. Experimental validation remains essential to confirm predicted structures, characterise molecular interactions and establish biological function. Likewise, benchmarking new computational methods against experimental data is critical for understanding both their capabilities and their limitations.

Rare genetic diseases and translational research.

Rare genetic diseases often receive less research attention and visibility than more prevalent and economically impactful conditions. Although each rare disease affects relatively few individuals, around 300 million people worldwide are estimated to live with one of over 7,000 recognised rare diseases, ~ 80 % of which have a genetic component [3]. Consequently, researchers often have a limited body of published evidence upon which to build. An inherent issue of studying rare diseases is limited patient numbers, with studies frequently relying on small cohorts or specialised experimental models, making independent validation particularly challenging. Confirming findings across multiple models, laboratories, patient-derived systems and cohorts increases confidence in potential disease mechanisms and therapeutic targets whilst reducing the risk of pursuing misleading observations. Equally important is the publication of carefully conducted negative findings and methodological improvements, which can prevent unnecessary duplication of effort and help direct limited resources towards the most promising avenues of research.

These three fields highlight a common principle, that for innovation to matter, it must be trusted. These fields also sit at the forefront of translational science, driving our understanding of disease and improving patient care. By encouraging submissions which emphasise validation, transparency and rigour, RevisX seeks to strengthen the foundations of interdisciplinary biomedical research. We invite researchers working within biomedical fields, particularly those mentioned here, to contribute replication, benchmarking and validation studies, protocol optimisation and negative results. At RevisX, we see reproducibility as a prerequisite for meaningful scientific progress, and we are proud to publish work which validates, tests and explores.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.